Pharma Is Poised For A COVID-19 Recovery; Will Q2 Deliver?

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.

Basketball rebound
Q2 could deliver a rebound for pharma manufacturers • Source: Alamy

Second quarter financial results are expected to mark a financial inflection point for big pharmaceutical manufacturers after nearly 18 months of navigating the uncertain commercial market for drugs amidst the COVID-19 pandemic. Revenues across the sector are expected to rebound in the quarter following a challenging first quarter, when drug makers posted mixed financial results and offered investors cautiously optimistic forecasts for the second half of the year.

As the industry hits the midpoint of 2021 and makes progress in its slow pandemic recovery, strong second quarter financial...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.